US 12,403,142 B2
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
Jing Wang, Lexington, MA (US); Troy David Patterson, Wilmington, MA (US); and Ze Tian, Brookline, MA (US)
Assigned to Curis, Inc., Lexington, MA (US)
Filed by Curis, Inc., Lexington, MA (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,567.
Application 17/557,567 is a continuation of application No. 16/565,921, filed on Sep. 10, 2019, granted, now 11,234,986.
Claims priority of provisional application 62/729,648, filed on Sep. 11, 2018.
Prior Publication US 2022/0249502 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 9/20 (2013.01); A61K 9/48 (2013.01); C07K 16/2818 (2013.01)] 9 Claims
 
1. A method of treating colon carcinoma in a subject in need thereof, comprising administering to the subject:
(a) a pharmaceutically acceptable salt of a compound of the formula:

OG Complex Work Unit Chemistry
 and
(b) a PD-1 signaling inhibitor, wherein the pharmaceutically acceptable salt of the compound and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective.